Randomized Phase II Trial to Evaluate Alisertib Alone or Combined With Fulvestrant for Women With Advanced, Endocrine-Resistant Breast Cancer
Phase of Trial: Phase II
Latest Information Update: 13 Jul 2017
At a glance
- Drugs Alisertib (Primary) ; Fulvestrant
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 10 Jul 2017 Status changed from not yet recruiting to recruiting.
- 10 Jun 2017 Biomarkers information updated
- 22 May 2017 Planned initiation date changed from 28 Apr 2017 to 28 Jul 2017.